AU6169501A - Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids - Google Patents

Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Info

Publication number
AU6169501A
AU6169501A AU6169501A AU6169501A AU6169501A AU 6169501 A AU6169501 A AU 6169501A AU 6169501 A AU6169501 A AU 6169501A AU 6169501 A AU6169501 A AU 6169501A AU 6169501 A AU6169501 A AU 6169501A
Authority
AU
Australia
Prior art keywords
tetrahydrocannabinol
cell proliferation
delta8
methods
decreasing cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6169501A
Other languages
English (en)
Inventor
Sumner Burstein
Lawrence Recht
Robert B Zurier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU6169501A publication Critical patent/AU6169501A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
AU6169501A 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids Pending AU6169501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
PCT/US2001/015916 WO2001087295A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
AU6169501A true AU6169501A (en) 2001-11-26

Family

ID=22760084

Family Applications (5)

Application Number Title Priority Date Filing Date
AU6169501A Pending AU6169501A (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
AU2001263217A Abandoned AU2001263217A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2001263217A Abandoned AU2001263217A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Country Status (13)

Country Link
US (2) US6448288B1 (enExample)
EP (2) EP1307188B1 (enExample)
JP (2) JP2003533479A (enExample)
CN (2) CN1273123C (enExample)
AT (1) ATE406156T1 (enExample)
AU (5) AU6169501A (enExample)
CA (2) CA2409005A1 (enExample)
DE (1) DE60135557D1 (enExample)
HU (2) HUP0700039A2 (enExample)
IL (3) IL152892A0 (enExample)
NZ (2) NZ523029A (enExample)
RU (2) RU2272620C2 (enExample)
WO (3) WO2001087297A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
DE60320784D1 (de) * 2002-06-06 2008-06-19 Yissum Res Dev Co Stände zur modulierung des knochenwachstums
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
AU2006297300B2 (en) * 2005-09-29 2012-05-10 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8546401B2 (en) 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
CN1452485A (zh) 2003-10-29
CN1273123C (zh) 2006-09-06
WO2001087295A8 (en) 2003-04-10
EP1307188A4 (en) 2005-07-06
WO2001087296A1 (en) 2001-11-22
US20040225011A1 (en) 2004-11-11
WO2001087297A1 (en) 2001-11-22
IL152892A0 (en) 2003-06-24
DE60135557D1 (de) 2008-10-09
AU2001261695B2 (en) 2005-06-16
US6448288B1 (en) 2002-09-10
IL152891A0 (en) 2003-06-24
HUP0700039A2 (en) 2007-05-02
AU2001263217A1 (en) 2001-11-26
EP1307186A1 (en) 2003-05-07
CA2409005A1 (en) 2001-11-22
US20020022653A1 (en) 2002-02-21
AU6468001A (en) 2001-11-26
CA2408961A1 (en) 2001-11-22
JP2003533479A (ja) 2003-11-11
NZ523028A (en) 2004-09-24
RU2273476C2 (ru) 2006-04-10
ATE406156T1 (de) 2008-09-15
NZ523029A (en) 2004-11-26
JP2003533478A (ja) 2003-11-11
EP1307186A4 (en) 2005-10-19
HUP0700038A2 (en) 2007-05-02
US6914072B2 (en) 2005-07-05
AU2001264680B2 (en) 2006-09-14
CN1447685A (zh) 2003-10-08
CN1227007C (zh) 2005-11-16
WO2001087295A1 (en) 2001-11-22
EP1307188B1 (en) 2008-08-27
RU2272620C2 (ru) 2006-03-27
EP1307188A1 (en) 2003-05-07
IL152892A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
IL152891A0 (en) Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
AU2001273728A1 (en) Arrangement for connecting planar components
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
AU2002316074A1 (en) System for quantifying edema
AU2002211663A1 (en) Nf-$g(k)b inhibitors
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2001283161A1 (en) Pumping arrangement for fiber amplifiers
HUP0304079A3 (en) Carcass alignment system for carcass splitter
AU2002235298A1 (en) Hydroformed running board
AU2002331595A1 (en) Novel vasoconstrictor cannabinoid analogs
AU2002351021A1 (en) Kit for reducing aching caused by pde-v inhibitors
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man
AU2002243647A1 (en) Novel mesogens
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator
AU2001268268A1 (en) Latin draw poker
HK1065532A (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
AU2002315472A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
IL150609A0 (en) Polarizing beam splitter
TW506650U (en) Improved structure for splitter
AU2002250319A1 (en) Polarization combiner/splitter
AU2002359685A1 (en) Cryogenic processes for treating pantyhose
TW428765U (en) Light guiding plate used for back-light system
GB0120215D0 (en) Improved architecture for on-line transactional display